Medplus Health Services Ltd (MEDPLUS) is currently trading at 626.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

MedPlus Health Services is an organised pharmacy retailer operating an integrated offline and online network, complemented by diagnostic services. The company serves approximately 860 cities through 5,642 stores across 13 states and one union territory, offering branded medicines, private-label products, non-pharmaceutical products, home delivery and store-pickup services. MedPlus delivered strong Q2 FY2027 revenue growth of 21.3% year-on-year to ₹20,371 million, while operating EBITDA increased 10.7% to ₹981 million. Sequentially, operating EBITDA rose 50.7%, reflecting recovery from the weaker first quarter, although first-half operating EBITDA grew only 1.1% because margins remained under pressure. The company added 166 net stores during the quarter, including 219 openings and 53 closures, taking the network to 5,642 outlets. However, 29% of stores are less than two years old, creating meaningful near-term maturity potential but also keeping expansion-related costs, inventory requirements and pre-operative losses elevated. MedPlus’s established stores demonstrated attractive economics, with 12-month-plus outlets reporting 13.2% revenue growth, 11.7% store-level EBITDA margins and 72.0% operating ROCE. This mature-store profitability supports the company’s cluster-based strategy, while younger stores and pre-operative investments currently dilute consolidated operating performance. The company’s omni-channel revenue reached ₹1,112 million in Q2 FY2027, supported by 735 delivery hubs and coverage of 3,441 pincodes. Its physical-store density enables a stated sub-two-hour delivery proposition, lower customer acquisition costs and lower delivery expenses compared with online-only pharmacy models.

Over the past 52 weeks, Medplus Health Services Ltd has traded between a low of ₹566.00 and a high of ₹1,020.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Medplus Health Services Ltd has a market capitalization of approximately 7,391.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Medplus Health Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,391.41 Cr, Medplus Health Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Medplus Health Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Medplus Health Services Ltd is 35.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Medplus set a maximum buyback price of ₹750 per equity share, payable in cash. The price is a ceiling for open-market purchases, rather than a stated price at which every share will be acquired. Purchases below ₹750 could allow Medplus to buy more shares within the ₹130 crore maximum.

Medplus Health Services Limited has scheduled a board meeting for November 6, 2026 to consider a buyback of fully paid-up equity shares. The exchange intimation was filed on October 30, 2026.

MedPlus Health Services' board is scheduled to consider and approve the Q2 FY27 and half-year results on October 27, 2026.

Consolidated net profit was ₹33.18 crore for the quarter ended June 30, down from ₹42.36 crore a year earlier, a decline of about 22%.